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Abstract
Purpose of Review Opioid use disorder (OUD) remains a national epidemic with an immense consequence to the United States’
healthcare system. Current therapeutic options are limited by adverse effects and limited efficacy.
Recent Findings Recent advances in therapeutic options for OUD have shown promise in the fight against this ongoing health
crisis. Modifications to approved medication-assisted treatment (MAT) include office-based methadone maintenance, implant-
able and monthly injectable buprenorphine, and an extended-release injectable naltrexone. Therapies under investigation include
various strategies such as heroin vaccines, gene-targeted therapy, and biased agonism at the G protein-coupled receptor (GPCR),
but several pharmacologic, clinical, and practical barriers limit these treatments’ market viability.
Summary This manuscript provides a comprehensive review of the current literature regarding recent innovations in OUD
treatment.
Keywords Opioids . Substance abuse . Opioid epidemic . Opioid use disorder
Introduction
Opioids are an essential component of the management of
perioperative pain and cancer-related pain. They are the oldest
and most efficacious group of drugs for managing severe pain.
Opioids act on opioid receptors that are located along the
nociceptive pathway, found on multiple presynaptic and post-
synaptic nerve terminals [1]. However, the misuse of these
medications in the treatment of chronic pain has contributed
greatly to the opioid crisis [2]. The opioid epidemic has de-
veloped into a major public health crisis related to the abuse of
prescription opioids, rise in heroin use, and increased avail-
ability of high-potency synthetic opioids. In 2019, drug over-
dose deaths increased 4.6% to 70,980 with over 70% involv-
ing opioids [3]. Opioid agonist therapy (OAT) with metha-
done or buprenorphine remains the gold standard for the treat-
ment of opioid use disorder (OUD) [4]. Although effective,
OAT has undesirable effects including abuse liability, respi-
ratory depression, cardiac arrhythmias, immunosuppression,
and hyperalgesia. Additionally, it requires patient participa-
tion in a maintenance program with no universal agreement
on the length of therapy, with approximately 40–60% of
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patients relapsing while on maintenance therapy [2]. The cur-
rent limitations and subpar outcomes of OUD treatment have
led to the study and research of new targeted therapies. This
review, therefore, focuses on recent advancements in novel
pharmacological treatment in OUD.
Opioid Use Disorder
The Diagnostic and Statistical Manual of Mental Disorders,
fifth edition (DSM-5), defines opioid use disorder as a prob-
lematic pattern of opioid use leading to clinically significant
impairment or distress [5]. The full diagnostic criteria for
OUD are outlined in Table 1 per DSM-5. OUD is a chronic
disease that affects over 16million people worldwide and over
2.1 million in the USA [6]. A hallmark of OUD is the “intense
cravings” that lead to compulsive drug seeking and use de-
spite harmful consequences [7]. Opioid addiction has become
a substantial economic burden on the United States economy,
with an estimated economic cost of more than $500 billion per
year [8]. OUD is a complex medical disease with multifaceted
individual, social, and economic factors.
It is imperative to understand the neurobiology behind opi-
oid tolerance, dependence, and withdrawal, which culminates
clinically as opioid addiction or OUD. Repeated exposure to
opioids first results in tolerance, which is the need to take
higher amounts of a drug in order to achieve a similar euphoric
effect [9, 10]. Opioid tolerance occurs as opioid receptors in
the brain become less responsive to opioid stimulation,
requiring more drugs to produce the same pleasurable effect
[10]. Dependence manifests as an individual becomes suscep-
tible to withdrawal symptoms in the setting of acute cessation
of opioid use [7, 10]. Opioid withdrawal occurs in the locus
coeruleus of the brain, as opioid receptor activation suppresses
noradrenergic neurons and repeated opioid exposure leads to
increased activity of these neurons [10, 11]. Opioid withdraw-
al symptoms include abdominal pain, nausea, vomiting, diar-
rhea, lacrimation, rhinorrhea, piloerection, yawning, sneezing,
elevated blood pressure, and elevated heart rate [12]. These
symptoms can be agonizing, sometimes even life-threatening,
and perpetuate drug-seeking behavior. This vicious cycle of
dependence and withdrawal has prompted the investigation
into long-acting active opioids for the treatment of OUD.
Current Treatment Options
The Center for Disease Control and Prevent (CDC) states that
medication-assisted treatment (MAT) remains the best treat-
ment option for OUD [13]. Strong evidence supports long-
term opioid therapy as superior to abstinence-based treatment
or withdrawal management alone, claiming these methods are
associated with increased rates of relapse, morbidity, and
death, and are therefore not recommended [14, 15]. There
are currently three classes of medications historically used
for treatment: full-opioid agonists, partial opioid agonists,
and opioid antagonists. The present FDA-approved medica-
tions for maintenance treatment of OUD in the USA are meth-
adone, buprenorphine, and naltrexone, as further detailed in
Table 2 [16•]. These maintenance programs are typically
paired with counseling and behavioral therapy such as
cognitive-behavioral therapy (CBT) [17].
Methadone
Methadone was introduced to the USA in 1947 as an opioid
analgesic, with methadone maintenance treatment (MMT)
subsequently beginning in 1965 in response to the New
York City heroin epidemic [18]. Methadone is an oral pure
MOR agonist, with some agonistic effects on KOR and DOR,
a slow onset and offset of action, and the ability to curtail the
withdrawal effects and cravings from opioids. A licensed phy-
sician at a specialty treatment center that is certified by the
Substance Abuse and Mental Health Services Administration
and registered with the Drug Enforcement Administration
(DEA) can prescribe methadone for addiction [19]. MMT
generally has three phases: induction, stabilization, and main-
tenance. The induction phase starts at 15 to 30 mg daily,
reaching 50 to 80 mg by week two, and finally increased to
the optimal effective dose of 80 to 100 mg [20]. The mainte-
nance phase begins at week six with treatment lasting a min-
imum of one year to indefinite use based on an individual’s
Table 1 DSM-5 criteria for OUD
DSM-5 criteria for opioid use disorder
Definition: OUD is a problematic pattern of opioid use leading to
problems or distress, with at least two of the following occurring within
a 12-month period:
1. Taking larger amounts or taking drugs over a longer period than
intended.
2. Persistent desire or unsuccessful efforts to cut down or control opioid
use.
3. Spending a great deal of time obtaining or using the opioid or
recovering from its effects.
4. Craving or a strong desire or urge to use opioids.
5. Problems fulfilling obligations at work, school, or home.
6. Continued opioid use despite having recurring social or interpersonal
problems.
7. Giving up or reducing activities because of opioid use.
8. Using opioids in physically hazardous situations.
9. Continued opioid use despite ongoing physical or psychological
problem likely to have been caused or worsened by opioids.
10. Tolerance (i.e., need for increased amounts or diminished effect with
continued use of the same amount).
11. Experiencing withdrawal (opioid withdrawal syndrome) or taking
opioids (or a closely related substance) to relieve or avoid withdrawal
symptoms.
Modified from the American Psychiatric Association’s DSM-5, 2013 [5]
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progress and motivation [20]. MMT has been an effective,
well-established treatment option for more than 50 years, de-
creasing mortality by 50% in those with OUD as well as
decreases in relapse, infection, and crime [20]. In comparison
to buprenorphine, MMT has higher retention rates and is more
effective for injection opioid users [15, 16]. Additionally,
methadone has antagonistic properties at N-methyl-D-
aspartate (NMDA) receptor, which produces not only analge-
sic effects but may also mitigate the development of tolerance
[21].
Despite its success, methadone is not a benign agent and is
associated with several adverse effects, including the potential
for abuse. Metabolism occurs through the cytochrome P450
(CYP450), primarily through CYP3A4 and CYP2B6, leading
Table 2 FDA-approved
medications for OUD and future
treatment options
FDA-approved medications for OUD Future treatment options
Methadone (PO)
• 80–150 mg/day
•Maintenance dosing is determined during the early
weeks of treatment following upward titration
• FDA approved in 1972
Buprenorphine-naloxone (SL or BUC)
• Suboxone®
• 8–24 mg/day buprenorphine
• 1–6 mg/day naltrexone
• 4:1 ratio of buprenorphine-naloxone
• FDA approved in 2002
Buprenorphine transdermal patch
• Butrans™
• 5 to 20 mcg/h doses




•Delivers steady state of medication over a 6-month
period
• FDA approved in 2016
Buprenorphine extended-release formulation (SQ)
• Sublocade®
• 80–300 mg/monthly injection




• Vivitrol®: 380 mg/monthly IM injection FDA
approved in 2010
• 50 or 100 mg/day orally
• Requires a patient to be opioid free for 7–10 days
before administration
Heroin vaccine
• Heroin-tetanus toxoid (TT) conjugated with adjuvants
alum and CpG ODN
• Reduced heroin potency by greater than 15-fold in
animal studies
• Beneficial for those with difficulty adhering to
maintenance therapy
CRISPR
• Gene-editing method with therapeutic potential
•GWAS superior to candidate gene studies as it prevents
inherent bias and can analyze a greater number of
polymorphisms
Biased agonism agents
• Mitragynine: natural product derived from a plant
• Oliceridine (TRV130): previously in clinical trials,
reapplied for continued trials this year
• PZM21: morphine-equivalent analgesia but concerns
for respiratory depression
• NAN: partial agonist that may mitigate opioid-induced
adverse effects
Ion channel targets
• Nav1.7, Nav1.8 inhibitors: tetrodotoxin, saxitoxin,
synthetic acyl sulfonamides
• Cav2.2 inhibitors: ziconotide, CNCB-2, physalin F
• TRPV-1 agonists: capsaicin, resiniferatoxin
KOR agonists
• Butorphanol: partial MOR with 20-fold higher affinity
to KOR
OREX-19
• Animal studies demonstrate mechanism similar to
buprenorphine/naltrexone
Medical cannabinoid
•Animal and clinical studies reduce opioid reward effect
and decrease cravings
• Dronabinol and nabilone: synthetic partial agonist
cannabinoids under investigation for analgesic effects
Cholinesterase Inhibitors
• May reduce opioid adverse effects without affecting
analgesia
Lorcaserin
• 5-HT agonist with animal studies demonstrating
reduced oxycodone cravings
FDA-approved medications modified from Kreek et al. 2019 [14]
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to variable effects due to enzyme polymorphisms and drug-
drug interactions [22]. Another major concern is QT prolon-
gation at effective dosages, also known as methadone toxicity
[23]. In this regard, a baseline EKG is recommended for any-
one being evaluated to start on methadone treatment. Those at
highest risk include the elderly, female gender, heavy alcohol
users, cardiopulmonary disease patients, and users of QT-
prolonging medications [15]. Additionally, access to a treat-
ment center continues to be an obstacle for patients as some
must travel hundreds of miles or into different states for treat-
ment [18, 24]. An alternative strategy to facilitate ease of
access may be to allow physician practices to prescribe meth-
adone, which is termed office-based methadone maintenance.
This method has been successfully trialed in the USA for
patients transferred from traditional methadone clinics [18].
Buprenorphine
Buprenorphine is a partial MOR agonist that was developed in
the 1970s for analgesia but was not approved for OUD in the
USA until 2002 [25•]. Similar to methadone, it has a long
functional half-life that assists with opioid withdrawal symp-
toms without the euphoric effects. The induction phase usual-
ly lasts 1 week with starting doses between 4 and 8 mg with
usually no more than 30 mg by the end of the week [20]. The
stabilization phase begins at week eight when cravings have
reduced until a stable dose has been reached, typically be-
tween 16 and 24 mg per day [20]. The maintenance phase
begins once a stable dose has been reached and lasts a mini-
mum of one year [20]. Related to its partial agonism,
buprenorphine has less potential for the dangerous side effects
of opioids but remains capable of mitigating opiate withdraw-
al symptoms [21, 26]. Any licensed physician under the Drug
Addic t ion Treatment Act of 2000 can prescr ibe
buprenorphine, allowing for office-based treatment of OUD
unlike methadone [27].
Buprenorphine is available in multiple FDA-approved
formulations for OUD: sublingual buprenorphine, combi-
nation sublingual buprenorphine and naloxone, transder-
mal patch, buprenorphine implant, and monthly injection
depot. Buprenorphine is manufactured in a sublingual for-
mulation as a result of its substantial first-pass metabolism
and lipid solubility, which results in excellent sublingual
bioavailability [21]. Combination buprenorphine and nal-
oxone (Suboxone®) was introduced to discourage intra-
venous abuse of buprenorphine alone, which can produce
a euphoric effect [28]. The low dose of naloxone will only
produce withdrawal effects if it is injected intravenously.
Transdermal buprenorphine (Butrans™) is available in
doses between 5 and 20 mcg/h that is used for chronic
pain requiring around-the-clock opioid therapy and may
be used for OUD treatment in the future [29]. A long-
acting buprenorphine implant called Probuphine was
approved by the US Food and Drug Administration in
2016 and delivers a steady state of medication over a 6-
month period [30•]. Some initial studies suggested the
implant had lower rates of relapse and improved quality
of life but may incur more potentially serious side effects
from insertion and removal of the implant when compared
to sublingual therapy [30•]. The FDA approved the
monthly subcutaneous buprenorphine injection depot
(Sublocade®) in 2017 with a currently recommended
treatment regimen of two 300 mg monthly doses with
subsequent 100 mg monthly doses [25•]. Trials are ongo-
ing to assess the formulation’s efficacy and the ideal pa-
tient population. The monthly injectable produces the
highest buprenorphine plasma concentration, and recent
studies suggest it may be best for those with greater phys-
ical dependence but should be avoided for direct induc-
tion due to safety concerns [25•].
Naltrexone
Naltrexone is a semi-synthetic opioid that acts as a competi-
tive antagonist at the MOR and partial agonistic activity at the
KOR in the central nervous system [31]. One approved ex-
tended-release, injectable formulation of naltrexone exists
called Vivitrol® (XR-naltrexone). This formulation was ap-
proved by the FDA in 2010 and is available as a 380 mg
monthly intramuscular injection [32]. Treatment initiation of
XR-naltrexone must occur during a period of abstinence from
opioids for 7–10 days in order to prevent acute withdrawal
symptoms [33]. A 2018 study comparing XR-naltrexone and
sublingual buprenorphine-naloxone shows similar safety and
efficacy, although it was more difficult to initiate treatment
with XR-naltrexone due to a longer period of opioid absti-
nence [34]. The difficulty initiating treatment with XR-
naltrexone is a well-recognized barrier, and current trials are
studying methods outside of opioid abstinence detoxification.
A 2017 randomized trial compared rapid induction with a
single dose of buprenorphine followed by increasing doses
of oral naltrexone (naltrexone-assisted detoxification) until
the administration of XR-naltrexone and a 7-day
buprenorphine taper fol lowed by a 7-day delay
(buprenorphine-assisted detoxification) until the first dose of
XR-naltrexone [35]. The study demonstrated improved thera-
peutic XR-naltrexone initiation among the naltrexone-assisted
cohort than the buprenorphine-assisted group, along with im-
proved withdrawal symptoms and treatment dropout rates
[35]. Another barrier with naltrexone is screening and moni-
toring of liver enzymes since it is not recommended in acute
liver failure, despite carrying a low risk of hepatoxicity.
Although promising, there continues to be obstacles to the
successful induction of XR-naltrexone therapy, in addition
to treatment continuity concerns that limit its overall clinical
utility.
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Recent Advances and Future Treatment
Options
Although current treatment models have shown efficacy in
preventing relapse and maintaining abstinence, approximately
40 to 60% of patients relapse while on MAT [36]. The latest
innovations aim to reduce the relapse rate, increase ease of
access, and improve upon previous safety profiles. Table 2
provides a summarized list of prospective therapies.
Biologics
An emerging treatment option for OUD is the use of biologics,
which entails vaccines or monoclonal antibodies. The model
incorporates immunopharmacotherapies, which are defined as
the use of specific antibodies, generated from a vaccine re-
sponse or administered monoclonal antibodies, to target the
abused drug in order to prevent action at its targeted receptor
[37]. The concept of a vaccine targeting opioids such as her-
oin, fentanyl, oxycodone, or hydrocodone is unique as a phar-
macokinetic approach as it prevents entry of the drug into the
central nervous system [38]. This can reduce opioid-related
effects such as respiratory depression and bradycardia, yet
continue to permit opioid reversal agents such as naloxone
and naltrexone to exert their desired effect [39]. A vaccine is
beneficial for individuals who have difficulty with adhering to
maintenance therapy or is more prone to relapse, as it may
prevent the rewarding effects of opioids without requiring
stringent dosing (although booster vaccines will likely be
required).
Vaccine design for OUD, specifically for heroin conjugate
vaccines, has explored an abundance of combinations includ-
ing haptens, carrier proteins, and adjuvants. Themost success-
ful and potentially clinically viable heroin vaccine is a heroin-
tetanus toxoid (TT) conjugated with adjuvants alum and
cytosine-guanine oligodeoxynucleotide (CpG ODN), which
has been used as a benchmark for new vaccine component
combinations [40, 41]. This vaccine was studied on rhesus
monkeys and mice, demonstrating reduced heroin potency
by greater than 15-fold, generating significant anti-heroin
IgG titers, and preventing cross-reactivity with other clinically
significant opioids [40]. A 2018 study explored the adjuvants
TLR3 agonist, a virus-derived double-stranded RNA
(dsRNA), and TLR 9 agonist, which is CpG ODN 1826
[41]. Each agonist alone produced strong anti-heroin antibody
titers but a combination of the two agonists failed to improve
efficacy [41, 42]. Vaccines directed against other opioids such
as fentanyl, oxycodone, and hydrocodone have generated pos-
itive results as demonstrated by reduced analgesic potency
following administration in a mouse model [38].
Designing a clinically viable vaccine for OUD presents
several challenges and barriers. The concept of creating an
anti-heroin vaccine that can immediately neutralize molecules
within minutes requires a fast-acting, highly potent antibody
[38]. The rapid metabolism of heroin to 6-acetylmorphine (6-
AM) and morphine requires a creative solution to create a
vaccine with antibodies to not only the target but its metabo-
lites. A successful model is a hapten design with greater than a
10-fold higher affinity for 6-AM than heroin with no affinity
to morphine since morphine does not readily cross the blood-
brain barrier [40, 43]. A common issue among all vaccines is
developing one that produces an efficacious antibody re-
sponse, and a heroin vaccine is no different [40, 41]. Even if
these hurdles are overcome, the most significant challenge is
to show clinical benefit against currently recommended treat-
ment. A 2019 study comparing the heroin-TT conjugate vac-
cine and continuous depot naltrexone in animals indicates
naltrexone decreased the antinociceptive potency of heroin
and its metabolites more effectively than this heroin vaccine
formulation [43]. This suggests the limited clinical utility of
this vaccine formulation as monotherapy for OUD. Despite
these findings, the vaccine is shown to attenuate the
antinociceptive potency of naltrexone, suggesting substantial
promise as an adjunctive therapy for currently approved main-
tenance therapies [43].
Gene-Targeted Therapy
There is a significant genetic component to OUDwith variants
and polymorphisms that are potential targets for therapy.
Candidate gene studies have identified variants in specific
genes that influence OUD risk. For instance, the OPRM1 gene
encodes the MOR and has exhibited specific polymorphisms,
such as two variants rs1799972 and rs1799971 that alter the
downstream reward pathway in those with OUD, rendering it
an attractive option for targeted therapy [44]. The issue with
this approach is inherent bias, which can leave other relevant
genes unaccounted for since the analyzed genes exhibit a
known connection to OUD [44]. Advances in computer pro-
cessing have led to more extensive analyses over a greater
number of polymorphisms across the entire genome with
genome-wide association study (GWAS). This method has
discovered new associations with variants, such as single-
nucleotide polymorphisms (SNPs) in potassium voltage-
gated channel subunits KCNC1 and KCNG2 [45]. This chal-
lenge has the potential to lead to a clinically relevant biomark-
er for OUD, a task the Psychiatric Genomics Consortium is
currently undertaking in a GWASwith over 100,000 addicted
patients [46••]. The individual variability with pharmacother-
apy for opioid addiction may have a genetic influence implicit
through GWAS to identify SNPs that could alter plasma drug
levels [45]. Although GWAS has discovered significant vari-
ants, these findings have been inconsistent across different
studies, implying that OUD is either overwhelmingly poly-
genic or that the studies are underpowered [44]. CRISPR, a
gene-editing method, is a potential therapeutic option for
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OUD if there are specific genetic defects that may be changed
for prevention [47•].
Biased Agonism
Opioid receptors belong to the G protein-coupled receptor
(GPCR) superfamily, which undergoes conformational
changes when ligand bound to activate downstream pathways.
Initially, the GPCRwas viewed as an “on-off” switch for these
cellular mechanisms. However, recent evidence demonstrates
a functional selectivity or biased agonism at specific receptor-
effector complexes, which can induce a specific conformation
of the receptor and activate certain pathways [48••]. This fea-
ture can be utilized to provide the analgesic effect without the
known opioid adverse effects. MOR activation leads to
antinociception via G protein-dependent signaling and cyclic
adenosine monophosphate (cAMP) inhibition [49]. Opioid
adverse effects, such as respiratory depression, are thought
to be due to G protein-independent pathways via beta-
arrestin interactions, demonstrated in a study of beta-arrestin
2 knockout mice that displayed enhanced morphine analgesia
alongside reduce constipation and respiratory depression [50].
Mitragynine is a natural product derived from the plant
kratom that binds the MOR and activates G protein signaling,
providing strong analgesia without beta-2 arrestin recruitment
[51]. It is used as a medicinal plant in parts of Asia for fatigue
and pain but is classified by the drug enforcement agent
(DEA) in the USA as a schedule I drug, limiting further in-
vestigation of its therapeutic potential [52, 53]. Oliceridine
(TRV130) is a biased MOR agonist discovered by Trevena
with strongG protein signaling that exhibits analgesic efficacy
equivalent to morphine with weak beta-arrestin 2 recruitment
[48••]. In rodent studies, it produced less respiratory depres-
sion and a reduction of tolerance compared to morphine [54].
Repetitive treatments, however, demonstrated similar gastro-
intestinal dysfunction [54]. TRV130 is the first G protein-
biased MOR agonist to enter clinical trials, undergoing phase
III clinical trials in 2017 as a next-generation intravenous opi-
oid analgesic for moderate-to-severe pain in the post-operative
period [48••]. The FDA rejected Trevena’s drug application
for Oliceridine in 2018 citing concerns for abuse and overdose
potential similar to other opioids. Trevena reapplied earlier
this year to collect data onQT prolongation and confirm levels
of an inactive metabolite [55].
PZM21 is another G protein-biased MOR agonist with un-
detectable beta-arrestin 2 recruitment, discovered by simulat-
ing 3 million molecules binding to the computer model MOR
crystal structure, unveiling a compound that is chemically
different from other opioids [56]. The initial study demonstrat-
ed a highly specific and potent analgesic equivalent to mor-
phine with low MOR internalization [56]. However, a 2018
study demonstrated dose-dependent respiratory depression in
a similar fashion to morphine, dampening the initial
enthusiasm [56, 57]. 17-cyclopropylmethyl-3,14β-dihy-
droxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan
(NAN) is a G protein-biased partial agonist at the MOR and
DOR with low efficacy but high efficacy at the KOR [58•]. In
rodent studies, NAN was shown to antagonize agonist-
induced MOR internalization and intracellular calcium re-
lease, producing less withdrawal symptoms compared to nal-
trexone at similar doses [58•]. NAN may have therapeutic
potential by mitigating opioid-induced adverse effects, a
mechanism similar to naltrexone.
Ion Channel Targets
Novel analgesic therapies are targeting afferent pain pathways
through specific channel blockades that include voltage-gated
sodium channels, voltage-gated potassium channels, and tran-
sient receptor potential vanilloid 1 receptors (TRPV-1). These
novel analgesic targets are capable of being utilized in OUD
treatment. Voltage-gated sodium channels Nav 1.7 and Nav
1.8 isoforms are heavily expressed at the dorsal root ganglion
(DRG) and are crucial components in pain transmission by
initiating and propagating action potentials [59, 60].
Tetrodotoxin and saxitoxin are natural toxins that act as inhib-
i tors at Nav1.7 and Nav1.8 that have promising
antinociceptive effects in preclinical pain models [59].
Additionally, synthetic acyl sulfonamide Nav1.7 inhibitors
have shown to be effective analgesics in mouse models [61].
Voltage-gated N-type calcium channel Cav2.2 is concentrated
at presynaptic nerve terminals responsible for nociceptive ac-
tivity [62]. Ziconotide is a synthetic ω-conotoxin developed
for severe refractory pain in chronic pain patients that inhibits
Cav2.2 by blocking channel pores but is limited in its clinical
utility due to required intrathecal administration and a narrow
therapeutic window [63]. CNCB-2 and physalin F are current-
ly investigated Cav2.2 channels inhibitors with potentially
improved efficacy [64, 65]. TRPV-1 plays a role in inflamma-
tory pain, as these channels are concentrated at DRG neurons
activated by various stimuli including capsaicin [66].
Activation by capsaicin can initially lead to hyperalgesia;
however, it is hypothesized long-term exposure can deactivate
the TPRV-1 channels and disrupt the afferent nociceptive
pathways [67]. Resiniferatoxin is a TPRV-1 agonist with
greater efficacy than capsaicin that has demonstrated long-
lasting analgesic effects with intrathecal administration in an-
imal models and a human subject with severe cancer pain
[68]. Although these targets are studied as novel analgesics,
they are also prospects for use in OUD treatment.
Alternative Opioid Receptor Agonists
There are three subtypes of opioid receptors: μ (MOR), κ
(KOR), and δ (DOR). A majority of opioids are primarily
MOR agonists resulting in analgesia with known detrimental
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effects; however, there is extensive research utilizing agonistic
activity at the KOR and DOR subtypes. The KOR binds to
endogenous dynorphins producing an analgesic effect in a
similar biochemical nature as MOR with adverse effects such
as dysphoria and sedation [69]. Although investigative efforts
have focused on creating a new analgesic through this recep-
tor, it also has the potential for OUD treatment by mitigating
withdrawal symptoms with less respiratory depression com-
pared to MOR agonists [70]. Additionally, the dysphoric ef-
fects, perceived as an adverse effect, are preferred in OUD
treatment as it reduces their dependence potential compared
to the reinforcing euphoric effects of MOR agonists [71].
Butorphanol is a synthetic opioid acting as a partial MOR
agonist with a higher affinity for KOR that has demonstrated
greater efficacy and less dependence when compared to mor-
phine [72].
The DOR binds to endogenous enkephalins producing an
analgesic response similar to the other opioid subtype recep-
tors [69]. Similar to KOR agonists, DOR agonists are poten-
tially useful for OUD treatment with favorable anti-depressant
and anti-anxiolytic effects [73]. Although common opioid
side effects such as respiratory depression and constipation
are not associated with DOR agonists, rat models demonstrate
an increase in convulsive activity [48••]. KOR and DOR ag-
onists are potential targets for OUD treatment due to their
quality analgesic effects and desirable side effect profile.
Other Therapies
OREX-1019 is a compound that imitates the mechanism of
buprenorphine/naltrexone and produces a dose dependent in
MOR agonist effect of remifentanil with the added benefit of
low abuse potential [74]. It demonstrates promise for another
option in current treatments for OUD, aimed particularly at
relapse prevention [74]. The medical cannabinoid is a non-
conventional therapy that has regained traction since the le-
galization of marijuana in several states. Both rodent model
and pilot clinical studies indicate exposure to cannabidiol
(CBD) reduces the opioid reward effect while also
diminishing cravings, with results lasting weeks after CBD
exposure [8]. Synthetic cannabinoids dronabinol and nabilone
are partial agonists towards cannabinoid receptors that are
under investigation for their analgesic effects [75].
Alterations to the cholinergic system have effects on the opi-
oid reward circuit in the central nervous system, representing a
potential therapeutic target [76]. Related to the lack of phar-
macologic specificity in targeting acetylcholine receptors, this
has been challenging to study [76]. However, cholinesterase
inhibitors exhibit promising results in clinical studies by re-
ducing opioid adverse effects without reducing analgesia [76].
Lorcaserin is a 5-hydroxytryptamine agonist that has shown a
dose-dependent abstinence signal in smokers, with a 2017
rodent study demonstrating suppression of oxycodone self-
administration and cue-induced reinstatement [38, 77].
Conclusion
The opioid epidemic continues to inflict devastating conse-
quence on the health of the USA and worldwide. Substantial
strides have been made to increase awareness of OUD as a
serious healthcare issue and facilitate access to appropriate
management options. Significant improvement is required
with regard to treatment efficacy, availability, and retention.
Enhancements to current treatment options have shown prom-
ise, although the medical advancements of biologics, gene-
targeted therapy, and biased agonism demonstrate even great-
er potential. Ultimately, the clinical viability of current re-
search may determine the resolution of the opioid epidemic.
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